在子宫内膜异位症发育期间,MCP-1在Ser246促进ILK酸化,并影响怀孕结果
Upendra Kumar Soni1, Rupal Tripathi1,2, Pushplata Sankhwar3
1Endocrinology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Molecular human reproduction
|March 4, 2025
概括
单细胞化学吸引蛋白1 (MCP-1) 激活整合因相关激酶 (ILK),促进子宫内膜异位症的进展. 用化合物22抑制ILK抑制了小鼠模型中的病变发育和炎症,表明ILK是治疗点.
科学领域:
- 生殖生物学 生殖生物学
- 分子医学是分子医学.
- 免疫学 免疫学 免疫学
背景情况:
- 单细胞化学吸引蛋白1 (MCP-1) 在子宫内膜异位症中升高,但其作用尚不清楚.
- 整合素连接激酶 (ILK) 是一个下游分子,参与细胞过程.
- 在子宫内膜异位症中,MCP-1/化学因子 (C-C动机) 受体2型 (CCR2) 信号可能与子宫内膜异位症有关.
研究的目的:
- 研究MCP-1/CCR2-介导ILK信号在子宫内膜异位症中的作用.
- 评估ILK抑制在子宫内膜异位症管理中的治疗潜力.
主要方法:
- 使用小鼠子宫内膜异位症模型和人类子宫内膜细胞 (Hs832(C).TCs).
- 采用了免疫沉和分子对接研究.
- 在体内和体外使用ILK抑制剂化合物22 (CPD22).
主要成果:
- MCP-1通过ILK促进炎症和子宫内膜细胞入侵.
- 通过CPD22抑制ILK可以逆转这些影响,并抑制小鼠的病变进展.
- ILK和CCR2表达与患者的子宫内膜异位症正相关.
- CPD22抑制了ILK-Ser246酸化,并稳定了ILK与关键残留物的相互作用.
结论:
- MCP-1在Ser246激活ILK,导致子宫内膜异位症病变的发展.
- 用CPD22准ILK是对子宫内膜异位症的一种有前途的治疗策略.
- 改变的MCP-1-ILK信号与小鼠模型中的不良妊娠结果有关.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Oogenesis
63.3K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.3K


